Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world.

The Power Play by The Market Herald
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (TSX:HLS)

Fundamentals Snapshot (TSX:HLS)

Opinion & Analysis (TSX:HLS)

No current opinion is available.

Bullboard Posts (TSX:HLS)

Clarus Revise Target

4/27/2022 Clarus Securities Reiterated Rating Buy C$26.50
retiredcf - April 28, 2022


HLS Therapeutics Reiterated by Clarus Securities C$33.00 Buy
retiredcf - March 22, 2022


Still looking for a double. GLTA Canaccord Genuity’s Tania Armstrong-Whitworth lowered her HLS Therapeutics Inc. target by 25...
retiredcf - March 18, 2022


08:20 AM EDT, 03/17/2022 (MT Newswires) -- HLS Therapeutics Inc. (HLS.TO), a pharmaceutical company focusing on central nervous system...
retiredcf - March 17, 2022

More Good Looking Targets

A very illiquid stock and a very quiet BB but now might be the time to start paying attention. GLTA HLS THERAPEUTICS (TSE:HLS...
retiredcf - December 21, 2021

Canaccord 2022 Top Picks

Reopening and public access to bring the pulse back Investment recommendation HLS is a specialty...
retiredcf - December 21, 2021